Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Genital Herpes Overview 10 Therapeutics Development 11 Pipeline Products for Genital Herpes - Overview 11 Pipeline Products for Genital Herpes - Comparative Analysis 12 Genital Herpes - Therapeutics under Development by Companies 13 Genital Herpes - Therapeutics under Investigation by Universities/Institutes 15 Genital Herpes - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Genital Herpes - Products under Development by Companies 18 Genital Herpes - Products under Investigation by Universities/Institutes 19 Genital Herpes - Companies Involved in Therapeutics Development 20 Admedus Ltd 20 Agenus, Inc. 21 AiCuris GmbH & Co. KG 22 Foamix Pharmaceuticals Ltd. 23 Genocea Biosciences, Inc. 24 GenVec, Inc. 25 Immune Design Corp. 26 JN-International Medical Corporation 27 Mymetics Corporation 28 NanoBio Corporation 29 NanoViricides, Inc. 30 PaxVax, Inc. 31 Profectus BioSciences, Inc. 32 Redbiotec AG 33 Sanofi Pasteur SA 34 Shulov Innovative Science Ltd. 35 Starpharma Holdings Limited 36 Tomegavax, Inc. 37 Vaccibody AS 38 Vaxart, Inc. 39 Vical Incorporated 40 Genital Herpes - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 acyclovir - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Aspidasept - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 astodrimer - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 G-103 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GEN-002 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GEN-003 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 genital herpes (virus like particle) vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 genital herpes vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 genital herpes vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 genital herpes vaccine - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 genital herpes vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 genital herpes vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 GV-2207 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 herpes simplex virus [type 1, 2] vaccine - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 herpes simplex virus [type 1, 2] vaccine - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 herpes simplex virus 2 vaccine - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 herpes simplex virus 2 vaccine - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 herpes simplex virus 2 vaccine - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 herpes simplex virus 2 vaccine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 herpes simplex virus 2 vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 herpes simplex virus 2 vaccine - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 HSV-529 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 pritelivir - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Small Molecule for Genital Herpes - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 VCLHB-01 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 VCLHM-01 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 ZEP-3 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Genital Herpes - Dormant Projects 90 Genital Herpes - Discontinued Products 92 Genital Herpes - Product Development Milestones 93 Featured News & Press Releases 93 Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits 93 Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 93 Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing 94 Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging 95 Feb 03, 2016: Model helps decide drug dose for clinical testing 96 Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 96 Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 97 Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 98 Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 99 May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 99 Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 100 Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 101 Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 102 Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 103 Nov 07, 2013: Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107

Genital Herpes - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Genital Herpes - Pipeline Review, H2 2016’, provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Genital Herpes - The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects - The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Genital Herpes Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipelineTable of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Genital Herpes Overview 10 Therapeutics Development 11 Pipeline Products for Genital Herpes - Overview 11 Pipeline Products for Genital Herpes - Comparative Analysis 12 Genital Herpes - Therapeutics under Development by Companies 13 Genital Herpes - Therapeutics under Investigation by Universities/Institutes 15 Genital Herpes - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Genital Herpes - Products under Development by Companies 18 Genital Herpes - Products under Investigation by Universities/Institutes 19 Genital Herpes - Companies Involved in Therapeutics Development 20 Admedus Ltd 20 Agenus, Inc. 21 AiCuris GmbH & Co. KG 22 Foamix Pharmaceuticals Ltd. 23 Genocea Biosciences, Inc. 24 GenVec, Inc. 25 Immune Design Corp. 26 JN-International Medical Corporation 27 Mymetics Corporation 28 NanoBio Corporation 29 NanoViricides, Inc. 30 PaxVax, Inc. 31 Profectus BioSciences, Inc. 32 Redbiotec AG 33 Sanofi Pasteur SA 34 Shulov Innovative Science Ltd. 35 Starpharma Holdings Limited 36 Tomegavax, Inc. 37 Vaccibody AS 38 Vaxart, Inc. 39 Vical Incorporated 40 Genital Herpes - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 acyclovir - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Aspidasept - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 astodrimer - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 G-103 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GEN-002 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GEN-003 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 genital herpes (virus like particle) vaccine - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 genital herpes vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 genital herpes vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 genital herpes vaccine - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 genital herpes vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 genital herpes vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 GV-2207 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 herpes simplex virus [type 1, 2] vaccine - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 herpes simplex virus [type 1, 2] vaccine - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 herpes simplex virus 2 vaccine - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 herpes simplex virus 2 vaccine - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 herpes simplex virus 2 vaccine - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 herpes simplex virus 2 vaccine - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 herpes simplex virus 2 vaccine - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 herpes simplex virus 2 vaccine - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 HSV-529 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 pritelivir - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Small Molecule for Genital Herpes - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 VCLHB-01 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 VCLHM-01 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 ZEP-3 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Genital Herpes - Dormant Projects 90 Genital Herpes - Discontinued Products 92 Genital Herpes - Product Development Milestones 93 Featured News & Press Releases 93 Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits 93 Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 93 Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing 94 Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging 95 Feb 03, 2016: Model helps decide drug dose for clinical testing 96 Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 96 Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 97 Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine 98 Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015 99 May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003 99 Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences 100 Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 101 Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection 102 Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 103 Nov 07, 2013: Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 104 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107

Admedus Ltd Agenus, Inc. AiCuris GmbH & Co. KG Foamix Pharmaceuticals Ltd. Genocea Biosciences, Inc. GenVec, Inc. Immune Design Corp. JN-International Medical Corporation Mymetics Corporation NanoBio Corporation NanoViricides, Inc. PaxVax, Inc. Profectus BioSciences, Inc. Redbiotec AG Sanofi Pasteur SA Shulov Innovative Science Ltd. Starpharma Holdings Limited Tomegavax, Inc. Vaccibody AS Vaxart, Inc. Vical Incorporated